Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06442462
Other study ID # SPG302-SCZ-201
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 2024
Est. completion date October 2025

Study information

Verified date May 2024
Source Spinogenix
Contact Leo Chen, Dr.
Phone +61 3 9076 6564
Email Leo.Chen@monash.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.


Description:

This Phase 2 study will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia. This is a randomized, placebo-controlled study of SPG302 administered once daily for six weeks. This study will entail five visits to the study site for screening, study procedures, and receipt of investigational medication for use at home.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 32
Est. completion date October 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 45 Years to 65 Years
Eligibility Inclusion Criteria: - Age 45-65 - Primary diagnosis of schizophrenia - Clinical laboratory values within normal range or < 1.5 times ULN - Currently prescribed only one antipsychotic medication - Able and willing to provide written informed consent Exclusion Criteria: - Any physical or psychological condition that prohibits study completion - Known cardiac disease - Active or history of malignancy in the past 5 years - Serious infection that will not be resolved by first day of study intervention. - History of clinically significant CNS event or diagnosis in the past 5 years. - Acute illness within 30 days of Day 1 - History of suicidal behavior or suicidal ideation - History of chronic alcohol use or substance abuse in the last 5 years - HIV, hepatitis B and/or hepatitis C positive - Vaccines within 14 days - Receipt of investigational products within 30 days - Blood donation within 30 days - Pregnant or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SPG302
small synthetic molecule
Placebo
Placebo

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Spinogenix

Outcome

Type Measure Description Time frame Safety issue
Primary Positive and Negative Symptoms Scale (PANSS Score) as determined by clinician The PANSS is a scale to measure symptom severity of schizophrenia. Thirty symptoms of schizophrenia are evaluated by a clinician on a seven point sale, with 1 = absence of symptoms and 7 = extremely severe symptoms. This study will rate each score change by calculating the difference between baseline scale and completion of study intervention. 6 weeks
Primary Electroencephalogram analysis to assess brain electrical activity Electroencephalograms (EEG) will provide a non-invasive measurement of brain activity. This test will be used to measure specific brain responses to stimuli, including attention and decision making electrical activity and detection of unexpected changes in the auditory environment. 6 weeks
Primary Change in smooth pursuit eye tracking from baseline Participants will follow visual targets on a computer screen to assess for accuracy of following the item, and smoothness of eye movements. The visual target on the computer screen will follow several different tracking patterns and at various speeds. 6 weeks
Secondary Safety and tolerability of SPG302 in patients with schizophrenia Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results (SAEs). 6 weeks
Secondary Change in Global Impressions Improvement scale as determined by clinician Change in the Clinical Global Impression of Improvement (CGI-I) is a 3-item observer-rated scale that measures illness severity, global improvement or change, and therapeutic response. It is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). 6 weeks
Secondary Change in Global Impressions Severity scale as determined by clinician Change in the Clinical Global Impression of Severity (CGI-S) is a 3-item observer-rated scale that measures illness severity, global improvement or change, and therapeutic response. It is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). 6 weeks
Secondary World Health Organization Quality of Life - Abbreviated Assessment Questionnaire-brief version from baseline This is a 26-item questionnaire which collects self-reported data on physical health, psychological health, social relationships, and environmental health. Each section is scored from 1 to 5, with higher scores indicate higher quality of life. Scores from each section are then added together for an overall score, with higher score indicating higher quality of life. 6 weeks
Secondary Change in BACS (Brief Assessment Cognition Schizophrenia) score from baseline The BACS is a standardized neuropsychological test to assess the cognitive functions that are often impacted by schizophrenia. These functions are verbal memory, working memory, verbal fluency, processing speed, executive functioning, and motor speed. A higher score indicates higher functioning. 6 weeks
Secondary Change in Personal and Social Performance from baseline Personal and Social Performance (PSP) evaluates overall functioning in daily life. A higher score indicates higher functioning. 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A